Auryxia (Ferric Citrate) Patent Expiration, LOE Window & CMS Spending
Auryxia (Ferric Citrate) by Keryx Biopharmaceuticals: FDA Orange Book LOE 2030-07-21, 1 AB generics, $147.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Keryx Biopharmaceuticals |
| FDA Application & Pathway | N205874 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-07-21 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $147.1M |
| 2024 Medicare Part D Spend | $131.5M |
| 2024 Medicaid Spend | $15.6M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 22.7% 2-yr change) |